-
1.
Groenwald HF, Januzzi JL, Damman K, et al.. Anemia and mortality in heart failure patients: a systematic review and meta–analysis. J Am Coll Cardiol 2008; 52:818–827.
-
2.
He S-W, Wang L-X. The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. Congest Heart Fail 2009; 15:123–130.
-
3.
Anand IS. Anemia and chronic heart failure. J Am Coll Cardiol 2008; 52:501–511.
-
4.
Silverberg DS, Wexler D, Iaina A, et al.. The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clin Exp Nephrol 2009; 13:101–106.
-
5.
Boerrigter G, Costello-Boerrigter LC, Abraham WT, et al.. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular function. J Card Fail 2008; 14:539–546.
-
6.
Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009; 1790:682–693.
-
7.
Weiss G, Meusburger E, Radacher G, et al.. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003; 64:572–578.
-
8.
Vlahakos DV, Marathias KP, Madias NE. The role of the renin angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 2010;
-
9.
Abramov D, Cohen RS, Katz SD, et al.. Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fraction. Am J Cardiol 102:1069–1072.
-
10.
Ngo K, Kotecha D, Walters JA, et al.. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010; Jan 20;(1):CD007613.
-
11.
Ponikowski P, Anker SD, Szachniewicz J, et al.. Effect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol 2007; 49:753–762.
-
12.
Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al.. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007; 28:2208–2216.
-
13.
Ghali J, Anand I, Abraham WT, et al.. Randomized double blind trial of darbepoetin alpha treatment in patients with symptomatic heart failure and anemia. Circulation 2008; 117:526–535.
-
14.
Klapholz M, Abraham WT, Ghali JK, et al.. The safety and tolerability of darbepoetin alfa in patients with and symptomatic heart failure. Eur J Heart Fail 2009; 11:1071–1077.
-
15.
Abraham WT, Anand IS, Klapholz M, et al.. Treatment of anemia with darbepoetin alfa in heart failure. Congest Heart Fail 2010; 16:87–95.
-
16.
Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141:14–31.
-
17.
Naito Y, Tsujino T, Matsumoto M, et al.. Adaptive response of the heart to long term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009; 296:H585–593.
-
18.
Dong F, Zhang X, Culver B, et al.. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome C release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci 2005; 109:277–286.
-
19.
Murphy CL, Fitzimmons RJ, Jardine AJ, et al.. Routine assessment of iron status in all patients with heart failure may identify those at risk of developing anemia. Eur J Heart Fail 2007; 61:103.
-
20.
Grzeslo, Jankowska EA, Witkowski J et al.. Iron deficiency is a common finding in patients with stable chronic heart failure. Eur J Heart Fail (suppl) 2006; 5:132.
-
21.
De Silva R, Rigby AS, Klaus KA, et al.. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 2006; 98:391–398.
-
22.
Opasich C, Cazzola M, Scelsi L, et al.. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of in patients with chronic heart failure. Eur Heart J 2005; 26:2232–2237.
-
23.
Nanas JN, Matsouka C, Karageorgopoulos D, et al.. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48:2485–2489.
-
24.
Bolger AP, Bartlett FP, Penston HS, et al.. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48:1225–1227.
-
25.
Usmanov RI, Zueva EB, Silverberg DS, et al.. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency. J Nephrol 2006; 21:236–242.
-
26.
Toblli J, Lombrana A, Duarte P, et al.. Intravenous iron reduces NT- pro-BNP in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50:1657–1665.
-
27.
Okonko DO, Grzeslo A, Witkowski T, et al.. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol 2008; 51:103–112.
-
28.
Anker SD, Comin Colet J, Fillipatos G, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436–2448.
-
29.
Rozen-Zvi B, Gafter-Gvili A, Paul M, et al.. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52:897–906.
-
30.
McMurray JJV, Anand IS, Diaz R, et al.. Design of the reduction of events with darbepoetin alfa in Heart Failure (RED-HF): a phase III, anemia correction morbidity-mortality trial. Eur J Heart Fail 2009; 11:795–801.
Anemia Management in Cardiorenal Disease
Search for other papers by By Donald S. Silverberg in
Current site
Google Scholar
PubMed
Search for other papers by Dov Wexler in
Current site
Google Scholar
PubMed
Search for other papers by Adrian Iaina in
Current site
Google Scholar
PubMed
Search for other papers by Doron Schwartz in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory